Antihypertensive agents and renal transplantation

Hippokratia

Volumn 11, Issue 1, 2007, Pages 3-12

  Vergoulas, G ^a  

^a Aristotle University and Hippokration General Hospital   (Greece)

Author keywords

Anti hypertensive agents; Hypertension; Kidney transplantation

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CHLOROTHIAZIDE; COTRIMOXAZOLE; CYCLOSPORIN A; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETACRYNIC ACID; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LOOP DIURETIC AGENT; METFORMIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VASODILATOR AGENT; VERAPAMIL;

ANEMIA; CARDIOVASCULAR RISK; COUGHING; DIABETES MELLITUS; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GINGIVA HYPERPLASIA; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERPARATHYROIDISM; HYPERTENSION; HYPERURICEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INSULIN RESISTANCE; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MUSCLE WEAKNESS; NEPHROTOXICITY; PERIPHERAL EDEMA; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TACHYCARDIA; UREMIA;

EID: 33847693091     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. U.S. Renal Data System. USRDS 1998 annual report. Bethesda, MD: The National Institutes of Health- National Institute of Diabetes, Digestive and Kidney Diseases 1998
2. Ojo AO, Hunson GA, Wolfe RA, et al. Long - term survival in renal transplant recipients with graft function. Kidney Int 2000; 57:307-313
3. Riggato C, Folley RN, Kent GM, Guttman R, Parfrey PS. Long-term changes in left ventricular hypertrophy after renal transplantation. Transplantation 2000; 70:570-575
4. Jarowenko MV, Flechner SM, Van Buren CT, et al. Influence of cyclosporine on posttransplant blood pressure response. Am J Kidney Dis 1987; 10:98-103
5. Zeier M, Mandelbaum A, and Ritz E. Hypertension in the transplant patient. Nephron 1998;80:257-268
6. Vergoulas G, Miserlis Gr, Karasavvidou F, et al. The blood pressure after renal transplantation. A single centre experience. Hippokratia 2002; 6:62-70
7. nd World Congress on "Quality in Clinical Practice", Porto Carras, Chalkidiki, 3-6 June 2004, abstracts p. 108 (poster)
8. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998; 53:217-222
9. Vergoulas G, Miserlis Gr, Atmatzidis E, et al. Clinical risk factors on patient and graft survival after kidney transplantation. BANTAO Journal 2003; 1:261-263
10. Psaty BM, Smith NL, Siscovick DS, et all. Health outcomes associated with antihypertensive therapies used as first line agents: a systematic review and meta - analysis. JAMA 1997; 277:739-745
11. Howard RJ, Patton PR, Reed AI, et al. The changing causes of grft loss and health after kidney transplantation. Transplantation 2002; 73:1923-1928
12. Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA 2000; 283:633-638
13. Vergoulas G, Miserlis Gr, Karasavvidou F, et al. The blood pressure after renal transplantation. A single centre experience. Hippokratia 2001; 6:62-70
14. Kokado Y, Takahara S, Kameoka H, et al. Hypertension in renal transplant recipients and its effect on long term allograft survival. Transplant Proc 1996;28:1600-1602
15. Cosio FG, Falkenhain ME, Pesavento TE, et al. Relationships arterial hypertension and renal allograft survival in African-American patients. Am J Kidney Dis 1997; 29:419-417
16. WhitworthJA. Mechanisms of glucocorticoid - induced hypertension. Kidney Int 1987; 31:1213-1224
17. Kutkuhn B, Hollenbeck M, Weskoff A, et al. Renin secretion and captopril stimulation in hypertensive renal transplant recipients. Urol Int 1994; 52:82-86
18. First MR, Neylan JF, Rocher LL, Tejani A. Hypertension after renal transplantation. J Am Soc Nephrol 1994; 4(Suppl 1):S30-S38
19. Taler SJ, Textor SC, Canzanello VJ, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus and cyclosporine. Transplantation 1996; 62:1588-1592
20. Fryer JP, Granger DK, Leventhal JR, et al. Steroid related complications in the cyclosporine era. Clin Transplant 1994; 8:224-228
21. Veenstra DL, Best JH, Hornberger J, et al. Incidence and long term cost of steroid related side effects after renal transplantation. Am J Kidney Dis 1999; 33:829-833
22. Kasiske BL, Ballantyne CM. Cardiovascular risk associated with immunosuppression in renal transplantation. Transplant Rev 2002; 16:1-21
23. van den Dorpel MA, van der Meiracker AH, Lameris TW, et al. Cyclosporine A impairs the nocturnal blood pressure fall in renal transplant recipients. Hypertension 1996; 28:304-307
24. de Mattos AM, Olyaei AJ, Bennett WM. Pharmacology of immunosuppressive medications used in renal diseases and transplantation. Am J Kidney Dis 1996; 28:631-637
25. Taler SJ, Textor SC, Canzanello VJ, et al. Cyclosporine - induced hypertension: Incidence, pathogenesis and management. Drug Saf 1999; 20:437-457
26. Haas M, Mayer G. Cyclosporine A - associated hypertension. Pathomechanisms and clinical consequences. Nephrol Dial Transplant 1997; 12:395-397
27. Takeda Y, Mitamori I, Wu P, et al. Effects of an endothelin receptor antagonist in rats with cyclosporine induced hypertension. Hypertension 1995; 26:932-937
28. Sander M, Lyson T, Thomas GD, et al. Sympathetic neural mechanisms of cyclosporine induced hypertension. Am J Hypertens 1996; 9(Suppl):S124-S127
29. Textor SC, Weisner R, Wilson DJ, et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993; 55:1332-1337
30. Margreiter R. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in renal transplantation. A randomized multicentre study. The European Tacrolimus vs Ciclosprine micoeulsion Renal Transplantation Study Group. Lancet 2002; 359:741-746
31. Morales JM. Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation. Kidney Int 2002; 62(Suppl 82):S81-S87
32. Platz DP, Sollinger HW, Hullet DA, et al. RS-61443, a new potent immunosuppressive agent. Transplantation 1991; 51:27-31
33. European Mycophenolate Mofetil Cooperative Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345:131-1325
34. Ojo AO, Meier -Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independently of acute rejection. Transplantation 2000; 69:2405-2409
35. Kahan BD Camardo JS. Rapamycin: Clinical results and future opportunities. Transplantation 2001; 72:1181-1193
36. Sollinger HW, U.S. Renal Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60:225-232
37. Vanrenterghem Y, Lebranchu Y, Hene R, et al. Double blind comparison of two cortical regimens plus mycophenolate ofetil and cyclosporine for prevention of acute renal allograft rejection. The Steroid Dosing Study Group. Transplantation 2000; 70:1352-1359
38. Steroid Withdrawal Study Group. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil. A prospective randomised trial. Transplantation 1999; 68:1865-1874
39. Schnuelle P, Van Der Heide JH, Tegzess A, et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002; 13:536-543
40. Morales JM, Wramner L, Kreis H, et al. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2:436-442
41. National Kidney Foundation k/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (suppl): 176-182
42. Mailloux LU, Levey AS. Hypertension in patients with chronic renal disease. Am J Kidney Dis 1998; 32(Suppl 5): S120-S141
43. European best practice guidelines. Nephrol Dial Transpalnt 2002; 17(Suppl 4): S25-S26
44. Neutel JM. Metabolic manifestations of low-dose diuretics. Am J Med 1996; 101:71S-82S
45. Johnson AG, Nguyen TV, Day RO. Do non steroidal antiinflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300,
46. Swan SK. Diuretic strategies in patients with renal failure. Drugs 1994;48:380-385
47. Ellison DH. The physiologic basis of diuretic synergism : its role in treating diuretic resistance. Ann Intern Med 1991;114:886-894
48. Hoes AW, Grobbee DE, Lubsen J, et al. Diuretics, beta blockers and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995;123:481-487
49. West C, Carpenter BJ, Hakala TR. The incidence of gout in renal transplant recipients. Am J Kidney Dis 1995;123:481-487
50. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36:646-661
51. Dawidson I, Rooth P. Improvement of cadaver renal transplantation outcomes with verapamil. A review. Am J Med 1991; 90:37S
52. Bia MJ, Tyler K. Evidence that calcium channel blockade prevents cyclosporine-induced exacerbation of renal ischemic injury. Transplantation 1991;51:293-295
53. Dawidson I, Rooth P, Always C, et al. Verapamil prevents post-transplant delayed function and cyclosporine A nephrotoxicity. Transplant Proc 1990;22:1379-1380
54. Dawidson I, Rooth P, Lu C, et al. Verapamil improves the outcome after cadaver renal transplantation. J Am Soc Nephrol 1991; 2:983-990
55. Romero JC, Raij L, Granger JP, et al. Multiple effects of calcium entry blockers on renal function in hypertension. Hypertension 1987; 10:140-151
56. Chanard J, Toupance O, Lavaud S, et al. Amlodipine reduces cyclosporine - induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant 2003; 18:2147-2153
57. Martinez - Castelao A, Hueso M, Sanz V, et al. Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril and deoxazocin. Kidney Int 1998;68 Suppl:S130-S134
58. Morales JM, Rondriguez-Paternina E, Araque A, et al. Longterm protective effect of a calcium antagonist on renal function in hypertensive renal transplant patients on cyclosporine therapy: a 5-year prospective randomized study. Transplant Proc 1994;26:2598-2599
59. Tutone VK, Mark PB, Stewart GA, et al. Hypertension, antihypertensive agents and outcomes following renal transplantation. Clin Transplantation 2005; 19:181-192
60. Baroletti SA, Gabardi S, Magee CC, Milford EL. Calcioum channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction. Pharmacotherapy 2003; 23:788-801
61. Pesavento TE, Jones PA, Julian BA, et al. Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. J Am Soc Nephrol 1996;7:831-835
62. Guan D, Wang R, Lu et al. Effects of nicardipine on blood cyclosporine levels in renal transplant patients. Transplant Proc 1996;28:1311-1312
63. Grekas D, Dioudis C, Kalevrosoglou I, et al. Renal hemodynamics in hypertensive renal allograft recipients: Effect of calcium antagonists and ACE inhibitors. Kidney Int 1996, 49:597
64. Vanderschaaf MR, Hene RJ, Floor M, et al. Hypertension after renal transplantation: Calcium chanel blocker or converting enzyme blockade? Hypertension 1995,25:77
65. Bochicchio T, Sandoval G, Ron O, Perez-Grovas H, Bordes J, Herrera-Acosta J. Lisinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Kidney Int 1990,38:873
66. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-625
67. ALLHAT study. Major outcomes in high-risk hypertensive patients randomized to angiotensin -converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid lowering treatment to prevent heart attack.JAMA 2002; 288:2981-2997
68. Bakris G, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50:1641-1650
69. Bakris G, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAL study. Arch Intern Med 2003; 163:1555-1565
70. Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 1993;43:419-425
71. del Castillo D, Campistol JM, GuiradoL,et al.Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 1998,54(Suppl 68):S135
72. Suwelack B, Gerhardt U, Hausberg M, Rahn KH, Hohage H. Comparison of quinaril versus atenolol: effects on blood pressure and cardiac mass after renal transplantation. Am J Cardiol 2000; 86:583-585
73. Navar GL. The intrarenal rennin - angiotensin system in hypertension. Kidney Int 2004; 65:1522-1532
74. Sennesael J, Lamote J, Violet I, et al. Comparison of perindopril and amlodipine in cyclosporine - treated renal allograft recipients. Hypertension 1995;26:436-444
75. Bochicchio T, Sandoval G, Ron O, et al. Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Kidney Int 1990;38:873-879
76. Meyer MM. Post-transplant hypertension. In Bennett WM, McCarron DA, eds. Pharmacology and management of hypertension. New York, Churchill Livingstone, 1994:181-215,
77. Traindl O, Falger S, Reading S, et al. The effect of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993;55:1309-1313
78. Bergman SM, Curtis JJ. Possible mediators in hypertension: Renal factors. Semin Nephrol 1996;16:134-1390
79. Gaston RS, Julian BA, Curtis JJ. Post-transplant erythrocytosis: an enigma revisited. Am J kidney Dis 1994;24:1-11
80. Ritz E, Orth SR, Strzelezyk P. Angiotensin converting enzyme inhibitors, calcium channel blockers and their combination in the treatment of glomerular disease. J Hypertens 1997;15:Suppl :S21-S26
81. Moser M. Angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists and calcium channel blocking agents. J Am Coll Cardiol 1997;29:1414-1421
82. Vergoulas G, Miserlis Gr, Trellopoulos G, Antoniadis A. Evaluation of losartan in patients with renal transplantation. Hippokratia 2000;4:67-72
83. Vergoulas G, Miserlis Gr, Gakis D, Atmatzidis E, Anoniadis A. The use of valsartan in hypertensive renal transplant recipients. Hippokratia 2001; 5:61-68
84. Vergoulas G, Miserlis Gr, Papanikolaou V, et al. Angiotensin II type I receptor antagonists reduce proteinuria of hypertensive renal transplant recipients. Hippokratia 2001; 5: 165-171
85. Ducloux D, Saint-Hillier Y, Chalopin GM. Effect of losartan on haemoglobin concentration in renal transplant recipients: a retrospective analysis. Nephrol Dial Transplant 1997; 12:2683-86
86. Home S, Holzer H, Horina J. Losartan and renal transplantation. Lancet 1998; 351:285
87. Campistol JM, Inigo P, Jimenez W, et al. Losartan decreases plasma levels of TGF-β1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999;56:714-719
88. Vergoulas G, Miserlis Gr, Papanikolaou V, et al. Losartan versus losartan in the treatment of hypertension of renal transplant recipients. Hippokratia 2001; 5:156-164
89. Bakris G, Weir MR. Angiotensin - converting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause for concern? Arch Int Med 2000; 160:685-693
90. Elmfeldt D, Olofsson B, Meredith P. The relationship between dose and antihypertensive effect of four AT1 - receptor blockers. Differences in potency and efficacy. Blood Pressure 2002; 11:292-301
91. Hansson L. The relationship between dose and antihypertensive effect for different AT1 - receptor blockers. Blood Pressure 2001; 10 (Suppl 30): 33-39
92. Meredith PA. Clinical comparative trials of angiotensin II type I (AT1) - receptor blockers. Blood Pressure 2001; 10 (Suppl 3): 11-17
93. Shihab PS, Bennet WM, Tanner AM, et al. Andiotensin II blockade decreases TGF-beta and matrix proteins in cyclosporine nephropathy. Kidney Int 1997; 52:660-673
94. Weir MR, Wei C. The role of angiotensin II and TGF-beta on the progression of chronic allograft nephropathy. JRAAS 2001; 2(Suppl 1):S88-S1190
95. Stigant CE, Cohen J, Vivera M, et al. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35:58-63
96. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Cir Res 1990; 66:883-860
97. Ellis ML, Patterson JH. A new class of antihypertensive therpy: angiotensin II receptor antagonists. Pharmacotherapy 1996; 16:849-860
98. Balcells E, Meng QC, Johnson WH, Oparil S, Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997; 273:H1769-H1774
99. Hollemberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the rennin system. Hypertension 1998; 32:387-392
100. Siragy HM, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan - induced hypotension in conscious rats. Hypertension 2000; 35:1074-1077
101. Benz J, Oshrain C, Henry D, Avery C, Chiang YT, Gatlin M. Valsartan a new angiotensin II receptor antagonist: a double - blind study compring the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37:101-107
102. Conlin PR, Gerh WC, Fof J, Roehm JB, Boccuzzi SJ. Four year persistence patterns among patients initiating therapy with angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Theraput 2001; 23:1999-2009
103. Lorenz M, Billensteiner E, Bodingbauer M, et al. The effect of ACE inhibitor and angiotensin II blocker therapy on early posttransplant kidney graft function. Am J Kidney Dis 2004; 43: 1065-1070
104. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46
105. Suwelack B, Gerhard U, hausberg M, et al. Comparison of quinapril versus atenolol. Effects on blood pressure and cardiac mass after renal transplantation. Am J Cardiol 2000;86:583-585
106. Isobe N, Taniguchi K, Oshima S, et al. Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy and endothelial function in patients with hypertensive heart disease. Circ J 2002; 66: 993-999
107. Huysman FT, van Heusden FH, Wetxels JF, et al. Antihypertensive effect of beta blockade in renal transplant recipients with or without host kidneys. Transplantation 1988;46:234-237
108. Hausberg M, Barenbrock M, Hohage H, et al. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999; 33:862-868
109. Chobanian AV, Bakris G, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003; 289:2560-2572
110. Bell DS. Advantages of a third - generation beta blocker in patients with diabetes mellitus. Am J Cardiol 2004; 93:49-52).
111. Poole-Wilson PA, Cleland JG, Di Lenarda A, et al. Rational and design of the carvedilol or metoprolo European trial in patients with chronic heart failure : COMET. Eur J Heart Fail 2002; 4:321-329
112. Zezina L, Vessby B, Larsson E, Backman U, Fellstrom B. Carvedilol treatment of kidney graft recipients with chronic rejection. Clin Transplantation 1999; 13:484-490
113. Suter PM, Vetter W. Metabolic effects of antihypertensive drugs. J Hypertens 1995;13:S11-S17
114. Gress TW, Nieto FJ, Shahar WR, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factor for type 2 diabetes melltus. N Engl J Med 2000; 342:905-912